The approaches for addressing the TME in NSCLC encompass the use of checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 antibodies, which can enhance the activity of T cells against tumors. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.